What action has the FDA taken in regards to gadolinium based MRA contrast dyes and NSF/NSD?
In May 2007, the FDA requested that the five manufactures of gadolinium based contrast dyes include boxed warnings about the NSF/NSD risk on their products labels. The FDA also warned healthcare professionals that they should avoid using gadolinium based contrast dyes in any patients with kidney problems, and the agency advised that all patients should be screened for kidney disease before the administration of gadolinium. The FDA also started a monitoring program, and requested that healthcare providers report any instances of NSF/NSD linked to the use of gadolinium based contrast dyes to the agency.
